HIV Drugs Market by Distribution Channel, Therapy, and Geography - Forecast and Analysis 2023-2027

Published: Jun 2023

Pages: 158

SKU: IRTNTR75747

Snapshot

HIV Drugs Market Analysis Report 2023-2027:

The global HIV drugs market size is estimated to grow by USD 10,477.51 million at a CAGR of 5.46% between 2022 and 2027.

The increasingly higher detection of HIV AIDS worldwide is positively impacting the market growth. As access improves, HIV management is more effective and can result in a growing population who experience longer lifespans and require long-term treatment. This results in a greater number of HIV patients which will increase the demand for HIV drugs globally. In addressing these new challenges, advanced antiretroviral therapies and other treatment innovations will play a critical role. These new trends and advances shall result in the growth of the global HIV drug market in the foreseeable future.

Technavio has segmented the market into distribution channel, therapy, and geography.

The distribution channel segment is classified into offline and online.
The therapy segment is classified into combination HIV medicines, integrase inhibitors, non-nucleoside reverse transcriptase inhibitors, and others.
The geography segment is classified into North America, Europe, Asia, and the rest of the world (ROW).

It also includes an in-depth analysis of drivers, trends, and challenges.

What will be the size of the HIV Drugs Market During the Forecast Period?

To learn more about this report, Request Free Sample

HIV Drugs Market Segmentation by Distribution Channel, Therapy, and Geography Analysis

Distribution Channel Analysis

Offline segment

The market share growth by the offline segment will be significant during the forecast period. Offline distribution of HIV drugs by dispensing medications through pharmacies, hospitals, clinics, and healthcare facilities shall a vital role in the global market for HIV drugs. This is due to limited internet penetration or connectivity or a preference for in-person interactions with doctors, nurses, and other healthcare providers in certain regions of the world.

Get a glance at the market contribution of various segments View a PDF Sample

The offline segment was valued at USD 24,925.65 million in 2017. Certain people have a degree of trust and familiarity with physical healthcare options and providers, hence, contributing to the growth of the offline segment of the HIV drugs market during the forecast period.

Therapy Analysis

Combination HIV Medicines

The combination HIV medicines segment, also called ART, involves the administration of several drugs from different classes, such as NRTIs, integrase inhibitors, and fusion inhibitors to manage and treat HIV at different stages of its life cycle. This reduces the possibility of replication and increases the viral load, creating more potent and effective regimens that can inhibit the growth of the virus. They have turned a former deadly condition into a more manageable condition that can be avoided from escalation to AIDS. Hence, the Combination HIV medicines segment of the HIV drugs market is likely to witness growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 49% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Due to innovations and growth in medical research, advanced healthcare infrastructure, and increased awareness about HIV/AIDS, the North American region is the largest regional market for HIV drugs. Having a robust pharmaceutical industry, greater levels of government and private organizations interactions and collaborations have expanded the market growth. Newer innovations such as the usage of pre-exposure prophylaxis medication, the introduction of long-acting therapies, and gene-editing techniques like CRISPR/Cas9 hold great potential for the development of curative treatments in the long run. Improved access in underdeveloped regions, which are more vulnerable, is advancing HIV treatment and prevention strategies. Hence the above, Therefore, the above-mentioned changes are improving the growth of the regional HIV drugs market during the forecast period.

COVID Recovery Analysis

The COVID-19 pandemic with the closure of regional healthcare facilities and suspension of diagnostic services as well as procedures negatively impacted the HIV drugs market. However, large-scale vaccination and the resumption of pharmaceutical manufacturing and logistics after the easing of lockdown restrictions reduced R&D constraints. Hence, the demand for HIV drugs resumed from Q1 2021 with regular diagnostic services and treatments in North America operating. Hence, the North American HIV drug market is expected to witness growth during the forecast period.

Buy Now Full Report and Discover More

Key HIV Drugs Market Players

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market vendors, including:

AbbVie Inc. - The company offers HIV drugs such as Kaletra and Aluvia.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

HIV Drugs Market: Key Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.

Significant HIV Drugs Market Trends

Expanding access to HIV treatment is a key trend in the market. Increased government, international organizations, and NGO involvement have resulted in greater resource allocation to target the global HIV epidemic. Initiatives like the President Emergency Plan for AIDS Relief (PEPFAR) are a good example. This has resulted in improved infrastructure, better healthcare systems, and increased availability of HIV drugs globally. There is also the development of easier treatment regimens with simple administration and fewer resources, for instance into a single pill, which makes adherence simpler.

Additionally, the production of generic versions of HIV drugs that are more affordable makes access greater in developing and underdeveloped parts of the world. All these factors also contribute to the prevention of mother-to-child transmission (PMTCT) of the virus by providing antiretroviral drugs to pregnant women living with HIV. However, factors such as funding gaps, stigma, and healthcare infrastructure limitations are barriers that prevent universal access to treatment and hinder the market growth during the forecast period.

Major HIV Drugs Market Challenges

The increasing drug resistance among individuals is challenging market growth. Human immunodeficiency virus (HIV) has a high mutation rate which enables it to develop resistance to antiretroviral drugs used in treatment. If individuals do not follow the prescribed treatment regimen and are irregular, then the virus can mutate and develop resistance to the drugs. This can cause failure in antiretroviral drug treatment of HIV, causing the disease to progress further, potentially limiting the number of treatment options.

Additionally, drug-resistant strains of HIV can even be transmitted to others, posing far more deadly health risks to the public at large. This will require further healthcare investment and laboratory spending to identify the drug-resistant strains and treat the mutated version of the virus. Hence, increasing drug resistance is hindering the market growth during the forecast period.

Buy Now Full Report and Discover More

Key HIV Drugs Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global HIV Drugs Market Customer Landscape

Segment Overview

The HIV drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.

Distribution Channel Outlook (USD Million, 2017 - 2027)
- Offline
- Online

Therapy Outlook (USD Million, 2017 - 2027)
- Combination HIV medicines
- Integrase inhibitors
- Non-nucleoside reverse transcriptase inhibitors
- Others

Region Outlook (USD Million, 2017 - 2027)
- North America
  - The U.S.
  - Canada
- Europe
  - U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- Rest of World (ROW)
  - Australia
  - Argentina
  - Brazil

HIV Drugs Market Scope
Report Coverage	Details
Page number	158
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 5.46%
Market growth 2023-2027	USD 10,477.51 million
Market structure	Fragmented
YoY growth 2022-2023(%)	4.55
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 49%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Aspen Pharmacare Holdings Ltd, Aurobindo Pharma Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Cipla Ltd., Emcure Pharmaceuticals Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Labs Ltd., Johnson and Johnson Services Inc., Lupin Ltd., Macleods Pharmaceuticals Ltd., Merck and Co. Inc., Strides Pharma Science Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., and Cadila Pharmaceuticals Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this HIV Drugs Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the HIV Drugs Market between 2023 and 2027
Precise estimation of the size HIV drugs market and its contribution to the market in focus on the parent market
Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
Vendor landscape comparing criticality of inputs and factors of differentiation
Exclusive Matrix on vendor position and Classification
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
A thorough analysis of the market’s competitive landscape and detailed information about vendors
Comprehensive analysis of factors that will challenge the growth of HIV drugs market vendors

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Therapy
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global HIV drugs market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on global hiv drugs market 2017 - 2021 ($ million)

4.2 Distribution Channel Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)

4.3 Therapy Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Therapy Segment 2017 - 2021 ($ million)

4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Distribution Channel

6.1 Market segments
- Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)

6.2 Comparison by Distribution Channel
- Exhibit 32: Chart on Comparison by Distribution Channel
- Exhibit 33: Data Table on Comparison by Distribution Channel

6.3 Offline - Market size and forecast 2022-2027
- Exhibit 34: Chart on Offline - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Offline - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Offline - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Offline - Year-over-year growth 2022-2027 (%)

6.4 Online - Market size and forecast 2022-2027
- Exhibit 38: Chart on Online - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Online - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Online - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Online - Year-over-year growth 2022-2027 (%)

6.5 Market opportunity by Distribution Channel
- Exhibit 42: Market opportunity by Distribution Channel ($ million)
- Exhibit 43: Data Table on Market opportunity by Distribution Channel ($ million)

7 Market Segmentation by Therapy

7.1 Market segments
- Exhibit 44: Chart on Therapy - Market share 2022-2027 (%)
- Exhibit 45: Data Table on Therapy - Market share 2022-2027 (%)

7.2 Comparison by Therapy
- Exhibit 46: Chart on Comparison by Therapy
- Exhibit 47: Data Table on Comparison by Therapy

7.3 Combination HIV medicines - Market size and forecast 2022-2027
- Exhibit 48: Chart on Combination HIV medicines - Market size and forecast 2022-2027 ($ million)
- Exhibit 49: Data Table on Combination HIV medicines - Market size and forecast 2022-2027 ($ million)
- Exhibit 50: Chart on Combination HIV medicines - Year-over-year growth 2022-2027 (%)
- Exhibit 51: Data Table on Combination HIV medicines - Year-over-year growth 2022-2027 (%)

7.4 Integrase inhibitors - Market size and forecast 2022-2027
- Exhibit 52: Chart on Integrase inhibitors - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Data Table on Integrase inhibitors - Market size and forecast 2022-2027 ($ million)
- Exhibit 54: Chart on Integrase inhibitors - Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on Integrase inhibitors - Year-over-year growth 2022-2027 (%)

7.5 Non-nucleoside reverse transcriptase inhibitors - Market size and forecast 2022-2027
- Exhibit 56: Chart on Non-nucleoside reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Data Table on Non-nucleoside reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million)
- Exhibit 58: Chart on Non-nucleoside reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on Non-nucleoside reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%)

7.6 Others - Market size and forecast 2022-2027
- Exhibit 60: Chart on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 61: Data Table on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 62: Chart on Others - Year-over-year growth 2022-2027 (%)
- Exhibit 63: Data Table on Others - Year-over-year growth 2022-2027 (%)

7.7 Market opportunity by Therapy
- Exhibit 64: Market opportunity by Therapy ($ million)
- Exhibit 65: Data Table on Market opportunity by Therapy ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 67: Chart on Market share by geography 2022-2027 (%)
- Exhibit 68: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison
- Exhibit 69: Chart on Geographic comparison
- Exhibit 70: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2022-2027
- Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.4 Europe - Market size and forecast 2022-2027
- Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027
- Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 US - Market size and forecast 2022-2027
- Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)

9.8 Germany - Market size and forecast 2022-2027
- Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.9 China - Market size and forecast 2022-2027
- Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)

9.10 UK - Market size and forecast 2022-2027
- Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%)

9.11 Canada - Market size and forecast 2022-2027
- Exhibit 103: Chart on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 104: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 105: Chart on Canada - Year-over-year growth 2022-2027 (%)
- Exhibit 106: Data Table on Canada - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography
- Exhibit 107: Market opportunity by geography ($ million)
- Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 109: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 110: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 111: Overview on factors of disruption

11.4 Industry risks
- Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 113: Vendors covered

12.2 Market positioning of vendors
- Exhibit 114: Matrix on vendor position and classification

12.3 AbbVie Inc.
- Exhibit 115: AbbVie Inc. - Overview
- Exhibit 116: AbbVie Inc. - Product / Service
- Exhibit 117: AbbVie Inc. - Key news
- Exhibit 118: AbbVie Inc. - Key offerings

12.4 Aurobindo Pharma Ltd.
- Exhibit 119: Aurobindo Pharma Ltd. - Overview
- Exhibit 120: Aurobindo Pharma Ltd. - Product / Service
- Exhibit 121: Aurobindo Pharma Ltd. - Key offerings

12.5 Bristol Myers Squibb Co.
- Exhibit 122: Bristol Myers Squibb Co. - Overview
- Exhibit 123: Bristol Myers Squibb Co. - Product / Service
- Exhibit 124: Bristol Myers Squibb Co. - Key news
- Exhibit 125: Bristol Myers Squibb Co. - Key offerings

12.6 Cadila Pharmaceuticals Ltd.
- Exhibit 126: Cadila Pharmaceuticals Ltd. - Overview
- Exhibit 127: Cadila Pharmaceuticals Ltd. - Product / Service
- Exhibit 128: Cadila Pharmaceuticals Ltd. - Key offerings

12.7 Cipla Ltd.
- Exhibit 129: Cipla Ltd. - Overview
- Exhibit 130: Cipla Ltd. - Business segments
- Exhibit 131: Cipla Ltd. - Key news
- Exhibit 132: Cipla Ltd. - Key offerings
- Exhibit 133: Cipla Ltd. - Segment focus

12.8 Emcure Pharmaceuticals Ltd.
- Exhibit 134: Emcure Pharmaceuticals Ltd. - Overview
- Exhibit 135: Emcure Pharmaceuticals Ltd. - Product / Service
- Exhibit 136: Emcure Pharmaceuticals Ltd. - Key offerings

12.9 Gilead Sciences Inc.
- Exhibit 137: Gilead Sciences Inc. - Overview
- Exhibit 138: Gilead Sciences Inc. - Product / Service
- Exhibit 139: Gilead Sciences Inc. - Key news
- Exhibit 140: Gilead Sciences Inc. - Key offerings

12.10 GlaxoSmithKline Plc
- Exhibit 141: GlaxoSmithKline Plc - Overview
- Exhibit 142: GlaxoSmithKline Plc - Business segments
- Exhibit 143: GlaxoSmithKline Plc - Key news
- Exhibit 144: GlaxoSmithKline Plc - Key offerings
- Exhibit 145: GlaxoSmithKline Plc - Segment focus

12.11 Hetero Labs Ltd.
- Exhibit 146: Hetero Labs Ltd. - Overview
- Exhibit 147: Hetero Labs Ltd. - Product / Service
- Exhibit 148: Hetero Labs Ltd. - Key offerings

12.12 Johnson and Johnson Services Inc.
- Exhibit 149: Johnson and Johnson Services Inc. - Overview
- Exhibit 150: Johnson and Johnson Services Inc. - Business segments
- Exhibit 151: Johnson and Johnson Services Inc. - Key news
- Exhibit 152: Johnson and Johnson Services Inc. - Key offerings
- Exhibit 153: Johnson and Johnson Services Inc. - Segment focus

12.13 Lupin Ltd.
- Exhibit 154: Lupin Ltd. - Overview
- Exhibit 155: Lupin Ltd. - Product / Service
- Exhibit 156: Lupin Ltd. - Key news
- Exhibit 157: Lupin Ltd. - Key offerings

12.14 Merck and Co. Inc.
- Exhibit 158: Merck and Co. Inc. - Overview
- Exhibit 159: Merck and Co. Inc. - Business segments
- Exhibit 160: Merck and Co. Inc. - Key news
- Exhibit 161: Merck and Co. Inc. - Key offerings
- Exhibit 162: Merck and Co. Inc. - Segment focus

12.15 Sun Pharmaceutical Industries Ltd.
- Exhibit 163: Sun Pharmaceutical Industries Ltd. - Overview
- Exhibit 164: Sun Pharmaceutical Industries Ltd. - Product / Service
- Exhibit 165: Sun Pharmaceutical Industries Ltd. - Key offerings

12.16 Teva Pharmaceutical Industries Ltd.
- Exhibit 166: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 167: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 168: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 169: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 170: Teva Pharmaceutical Industries Ltd. - Segment focus

12.17 Viatris Inc.
- Exhibit 171: Viatris Inc. - Overview
- Exhibit 172: Viatris Inc. - Business segments
- Exhibit 173: Viatris Inc. - Key news
- Exhibit 174: Viatris Inc. - Key offerings
- Exhibit 175: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 176: Inclusions checklist
- Exhibit 177: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 178: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 179: Research methodology
- Exhibit 180: Validation techniques employed for market sizing
- Exhibit 181: Information sources

13.5 List of abbreviations
- Exhibit 182: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

hiv drugs market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis